Ra Pharmaceuticals (NASDAQ:RARX) Sets New 1-Year High at $46.00

Shares of Ra Pharmaceuticals Inc (NASDAQ:RARX) hit a new 52-week high on Thursday . The company traded as high as $46.00 and last traded at $45.78, with a volume of 4270112 shares trading hands. The stock had previously closed at $22.70.

RARX has been the topic of a number of research reports. BidaskClub lowered Ra Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday. Zacks Investment Research raised Ra Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. BMO Capital Markets set a $42.00 target price on Ra Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 7th. Raymond James downgraded Ra Pharmaceuticals from a “strong-buy” rating to a “market perform” rating in a research report on Monday, July 29th. Finally, ValuEngine downgraded Ra Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. One investment analyst has rated the stock with a sell rating, three have given a hold rating and nine have issued a buy rating to the company’s stock. Ra Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $38.63.

The company has a debt-to-equity ratio of 0.02, a current ratio of 15.30 and a quick ratio of 15.30. The stock has a 50 day simple moving average of $25.75 and a two-hundred day simple moving average of $26.08. The company has a market cap of $1.09 billion, a PE ratio of -22.23 and a beta of 1.34.

Ra Pharmaceuticals (NASDAQ:RARX) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.52) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.49) by ($0.03). As a group, equities analysts anticipate that Ra Pharmaceuticals Inc will post -1.97 EPS for the current fiscal year.

In other news, insider Simon Read sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $32.95, for a total value of $329,500.00. Following the transaction, the insider now owns 16,234 shares of the company’s stock, valued at $534,910.30. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Ramin Farzaneh-Far sold 10,595 shares of the business’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $25.26, for a total value of $267,629.70. Following the completion of the transaction, the insider now directly owns 8,521 shares in the company, valued at approximately $215,240.46. The disclosure for this sale can be found here. In the last quarter, insiders sold 51,190 shares of company stock valued at $1,479,624. 4.30% of the stock is owned by company insiders.

Large investors have recently added to or reduced their stakes in the company. Bank of Montreal Can grew its holdings in Ra Pharmaceuticals by 218.0% during the second quarter. Bank of Montreal Can now owns 3,832 shares of the company’s stock worth $115,000 after acquiring an additional 2,627 shares during the period. Marshall Wace LLP acquired a new stake in Ra Pharmaceuticals during the first quarter worth about $229,000. Virginia Retirement Systems ET AL increased its stake in Ra Pharmaceuticals by 12.9% during the second quarter. Virginia Retirement Systems ET AL now owns 10,500 shares of the company’s stock worth $316,000 after acquiring an additional 1,200 shares during the last quarter. State Board of Administration of Florida Retirement System acquired a new stake in Ra Pharmaceuticals during the second quarter worth about $373,000. Finally, Athanor Capital LP acquired a new stake in Ra Pharmaceuticals during the second quarter worth about $409,000. 91.59% of the stock is currently owned by institutional investors and hedge funds.

Ra Pharmaceuticals Company Profile (NASDAQ:RARX)

Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.

See Also: What does it mean to hold a stock in street name?

Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit